Conditions: Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response
Interventions: Drug: Rucaparib; Drug: Nivolumab; Drug: Placebo Oral Tablet; Drug: Placebo IV Infusion
Sponsors: pharmaand GmbH; Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT); Foundation Medicine
Active, not **RECRUITING NOW**
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.